Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

DRUGS > IMMUNO - Immunosuppressants > Flashcards

IMMUNO - Immunosuppressants Flashcards

1
Q

Immunosuppressant general use

A

Block lymphocyte proliferation and activation

Decrease ACUTE graft rejection by decreasing CELLULAR immunity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Immunosuppressant general toxicity

A

Long-term use increases risk of infections and cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Cyclosporin MOA

A 
Binds cyclophilin
to inhibit calcineurin
blocking NFAT dephosphorylation
so NFAT can't get into nucleus 
so no IL-2 TC

Blocks IL-2 TC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

cyclosporin use

A

Transplant rejection prophylaxis
Psoriasis
RA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cyclosporin toxicity

A 
NEPHROTOXICITY
Gingival hyperplasia
Hirsutism
HTN
hyperlipidemia
neurotoxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Tacrolimus (FK508) MOA

A 
Binds FKBP
To inhibit calcineurin
blocking NFAT dephosphorylation
so NFAT can't get into nucleus 
so no IL-2 TC

Blocks IL-2 TC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Tacrolimus (FK508) use

A

transplant rejection prophylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tacrolimus (FK508) toxicity

A

NEPHROTOXICITY
HTN
hyperlipidemia (more risk of DM)
neurotoxicity (more risk)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Sirolimus (rapamycin) MOA

A

binds FKBP
to inhibit mTOR
to block T-cell activation and B-cell differentiation

Inhibits cells RESPONSE to IL-2 (IL-2 activates mTOR)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Sirolimus (rapamycin) use

A

KIDNEY transplant rejection prophylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Sirolimus (rapamycin) toxicity

A 
Anemia
Thrombocytopenia
Leukopenia
Insulin resistance and hyperlipidemia
*NOT nephrotoxic*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Daclizumab MOA

A

monoclonal Ab to block IL-2R

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Daclizumab use

A

KIDNEY transplant rejection prophylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Daclizumab toxicity

A

Edema
HTN
Tremor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Basiliximab MOA

A

monoclonal Ab to block IL-2R

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Basiliximab use

A

KIDNEY transplant rejection prophylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Basiliximab toxicity

A

Edema
HTN
Tremor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Azathioprine MOA

A

Antimetabolite: blocks NT (purine) synthesis inhibiting lymphocyte proliferation
Precursor of 6-MP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Azathioprine use

A 
Transplant rejection prophylaxis
RA
Chrons
Glomerulonephritis
Other autoimmunes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Azathioprine toxicities

A

Leukopenia
Anemia
Thrombocytopenia

*6MP degraded by XO, so increased toxicity by allopurinol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Glucocorticoids MOA

A

Inhibits NF-KB, inhibiting cytokine TC, suppressing B and T cell function

22
Q

Random glucocorticoid toxicity:

A

Cushings
Psyhchosis
Cataracts
Avascular necrosis

23
Q

Alemtuzumab (target)

A

Cancer therapy: CD52

24
Q

Bevacizumab (target)

A

Cancer therapy: VEGF

25
Q

Cetuximab (target)

A

Cancer therapy: EGFR

26
Q

Rituximab (target)

A

Cancer therapy: CD20

27
Q

Trastuzumab (target)

A

Cancer therapy: HER2/neu

28
Q

Alemtuzumab (Clinical use)

A

Cancer therapy: CLL

29
Q

Bevacizumab (Clinical use)

A

Cancer therapy: Colorectal cancer, renal cell carcinoma

30
Q

Cetuximab (Clinical use)

A

Cancer therapy: Stage IV colorectal cancer, head and neck cancer

31
Q

Rituximab (Clinical use)

A

Cancer therapy: B-cell non-hodgkin lymphoma, CLL, rheumatoid arthritis, ITP

32
Q

Trastuzumab (Clinical use)

A

Cancer therapy: Breast cancer

33
Q

Adalimumab (Target)

A

Autoimmune therapy: Soluble TNF-alpha

34
Q

infliximab (Target)

A

Autoimmune therapy: Soluble TNF-alpha

35
Q

Eculizumab (Target)

A

Autoimmune therapy: Compliment protein C5

36
Q

Natalizumab (Target)

A

Autoimmune therapy: alpha4-integrin

37
Q

Etanercept (Target)

A

Decoy TNF-alhpa receptor (not monoclonal ab)

38
Q

Adalimumab (Clinical use)

A

IBD, rheumatoid arthriis, ankylosing spondylitis, psoriasis

39
Q

Infliximab (Clinical use)

A

IBD, rheumatoid arthriis, ankylosing spondylitis, psoriasis

40
Q

Eculizumab (Clinical use)

A

paroxysmal nocturnal hemoglobinuria

41
Q

Natalizumab (Clinical use) (+AE)

A

Multiple sclerosis, Crohn disease

*risk of PML

42
Q

ABCiximab (target)

A

Platelet glycoproteins IIb/IIIa

43
Q

Denosumab (target)

A

RANKL

44
Q

Digoxin immune fab (target)

A

digoxin

45
Q

Omalizumab (target)

A

IgE

46
Q

Palivizumab (target)

A

RSV F protein

47
Q

Ranibizumab (target)

A

VEGF

48
Q

ABCixumab (Clinical use)

A

Prevention of ischemic complications in percutaneous coronary intervention

49
Q

Denosumab (Clinical use)

A

Osteoporosis; prevents osteoclast maturation

50
Q

Omalizumab (Clinical use)

A

Allergic asthma; prevents IgE biding FcR1

51
Q

Palivizumab (Clinical use)

A

RSV prophylaxis for high risk infants

52
Q

Ranibizumab (Clinical use)

A

Neovascular age-related macular degeneration

DRUGS (41 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions